Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul 6;80(8):273.
doi: 10.1007/s00284-023-03366-1.

Repurposing Polyether Ionophores as a New-Class of Anti-SARS-Cov-2 Agents as Adjunct Therapy

Keerthana Gurukkalot #  1 , Vinoth Rajendran #  2
Affiliations
Review

Repurposing Polyether Ionophores as a New-Class of Anti-SARS-Cov-2 Agents as Adjunct Therapy

Keerthana Gurukkalot et al. Curr Microbiol. .

Abstract

The emergence of SARS-CoV-2 and its variants have posed a significant threat to humankind in tackling the viral spread. Furthermore, currently repurposed drugs and frontline antiviral agents have failed to cure severe ongoing infections effectively. This insufficiency has fuelled research for potent and safe therapeutic agents to treat COVID-19. Nonetheless, various vaccine candidates have displayed a differential efficacy and need for repetitive dosing. The FDA-approved polyether ionophore veterinary antibiotic for treating coccidiosis has been repurposed for treating SARS-CoV-2 infection (as shown by both in vitro and in vivo studies) and other deadly human viruses. Based on selectivity index values, ionophores display therapeutic effects at sub-nanomolar concentrations and exhibit selective killing ability. They act on different viral targets (structural and non-structural proteins), host-cell components leading to SARS-CoV-2 inhibition, and their activity is further enhanced by Zn2+ supplementation. This review summarizes the anti-SARS-CoV-2 potential and molecular viral targets of selective ionophores like monensin, salinomycin, maduramicin, CP-80,219, nanchangmycin, narasin, X-206 and valinomycin. Ionophore combinations with Zn2+ are a new therapeutic strategy that warrants further investigation for possible human benefits.

Keywords: Anti-virals; Co-infection; Ionophores; SARS-CoV-2; Zn2+.

PubMed Disclaimer

References

    1. Organization WHO (2022) COVID-19 weekly epidemiological update. Accessed 22 Feb 2022
    1. Mullin S et al (2022) Modeling pandemic to endemic patterns of SARS-CoV-2 transmission using parameters estimated from animal model data. PANS Nexus 1(3):pgac096
    1. Shaman J, Galanti MJS (2020) Will SARS-CoV-2 become endemic? Science 370(6516):527–529 - PubMed
    1. Katzourakis AJN (2022) COVID-19: endemic doesn’t mean harmless. Nature. https://doi.org/10.1038/d41586-022-00155-x - DOI - PubMed
    1. Jacobs LG et al (2020) Persistence of symptoms and quality of life at 35 days after hospitalization for COVID-19 infection. PLOS One 15(12) - PubMed - PMC

LinkOut - more resources